Page results
-
An exciting new project to recycle packaging from single-use items is projected to reduce the waste being incinerated from UCLH theatres by around 215kg a year.
-
Elderly patients suffering the most common type of heart attack may benefit from more invasive treatment, new research involving UCLH has shown.
-
Acute loss of sense of smell should be considered globally as a criterion for self-isolation, testing, and contact tracing for Covid-19 infection according to researchers at UCLH and UCL.
-
UCLH is making the change from single use to named reusable fabric theatre hats for staff working in operating theatres.
-
UCLH has treated the first brain cancer patient with immunotherapy prior to standard treatment as part of a pioneering trial.
-
UCLH and Whittington Health have a long history of working together to benefit patients, staff and our communities across Camden, Haringey, Islington and beyond. This includes services such as the virtual ward, orthopaedic surgery and paediatric dentistry.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
Specialist teams at UCLH and UCL are at the forefront of research which could bring hope to people who have been robbed of their sense of smell and taste after suffering the long-term legacy of COVID-19.
File results
-
FOI/2024/0371 - Acute myeloid leukaemia treatment
-
FOI/2024/0373 - Allogeneic stem cell transplants/ ECP (ExtraCorporeal Photopheresis) service
-
FOI/2024/0376 - Advice provided on topical medication for eczema patients
-
FOI/2024/0380 - Appraisal review/ Responsible Officer/ Revalidation Officer
-
FOI/2024/0381 - Proton Beam Therapy Centre material use, architectural technology and performance
-
FOI/2024/0385 - Immunoglobulin vials (by brands) distributed to patients
-
FOI/2024/0400 - Gestational Diabetes Mellitus (GDM) screening and fetal outcomes
-
FOI/2024/0402 - Various IT systems used at the Trust
-
FOI/2024/0401 - Hospital treatments for abortion complications
-
FOI/2024/0491 - Breast cancer treatment